Bodycam footage shows the moment police detained Mahdi Mohamud after he stabbed a couple at Manchester Victoria station in 2018.
Bodycam footage shows the moment police detained Mahdi Mohamud after he stabbed a couple at Manchester Victoria station in 2018.
FD7 Ventures Managing Partner, Prakash Chand, has gone on record today with his prediction that the price of Cardano (ADA) and Polkadot (DOT) could rise to approximately 20x within the next 2-3 years. His projection is based on the belief that institutional money will begin to flow into these platforms, including Ethereum, as more organizations realize the potential they have to change the world.
Trademark Brand, skin-friendly hand sanitizer and sanitizing wipes, offering direct sales, kits, subscriptions, bulk purchases and more has launched.
The "Global and Chinese Wear Plate Industry, 2021 Market Research Report" has been added to ResearchAndMarkets.com's offering.
Shares of discount retailer Burlington Stores rallied after it reported earnings. Here's what got investors so excited.
The "Network Function Virtualization (NFV) Market by Component, Virtualized Network Function, Application, End User - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
It's difficult to determine intent but San Jose Sharks forward Joachim Blichfeld could be facing a suspension for his hit on Nathan MacKinnon.
We put the two speed shoes head to head to see which improved our times
Political leaders in New Caledonia on Thursday agreed new terms for the sale of Vale's nickel business, including a majority stakeholding for local interests, seeking to resolve unrest over the planned sale. The deal signed by pro-independence and loyalist leaders in the French Pacific territory also cited a "technical and industrial partnership" with Tesla, under which the electric car company would source raw materials for batteries. Brazilian miner Vale's decision last year to sell its nickel mine and processing plant to a consortium including Swiss commodity trader Trafigura sparked fierce opposition from pro-independence groups.
As students return to school from March 8, we present the best non-medical coverings to take with them as they head back to the classroom
Larry Wahl, a vice president of the Orange Bowl and a former New York Yankees media relations head under George Steinbrenner, has died. Wahl died Wednesday at his home in Pompano Beach, Florida, son Alexander Wahl said Thursday. “Larry was truly one of the good guys,” longtime Orange Bowl CEO Eric Poms said.
Sono 2.545 i casi di coronavirus registrati oggi 4 marzo in Emilia Romagna. E secondo il bollettino quotidiano ci sono altri 25 morti. Non si abbassa dunque la curva dei contagi nella regione dove, dall’inizio dell’epidemia, si contano in tutto 270.155 casi di positività. I 2.545 nuovi casi si registrano su un totale di 38.231 tamponi eseguiti nelle ultime 24 ore. La percentuale dei nuovi positivi sul numero di tamponi fatti da ieri è del 6,7%. Dei nuovi 25 decessi, 6 sono in provincia di Forlì-Cesena (2 donne di 87 e 93 anni e 4 uomini di 60, 80, 82 e 87 anni), 4 in provincia di Ferrara (2 donne di 75 e 91 anni e 2 uomini di 84 e 87 anni), 4 in provincia di Modena (1 donna di 90 anni e 3 uomini di 66, 75 e 80 anni), 4 in provincia di Rimini (1 donna di 99 anni e 3 uomini di 83, 92 e 94 anni). Ancora, 3 in provincia di Reggio-Emilia (3 uomini di cui uno di 84 anni e due di 86), 2 in provincia di Bologna (1 donna di 99 anni e un uomo di 72 anni), 1 in provincia di Piacenza (un uomo di 93 anni) e 1 in provincia di Parma (1 donna di 90 anni). Non si registrano decessi di persone residenti in provincia di Ravenna. In totale, dall’inizio dell’epidemia i decessi in regione sono stati 10.675. Continua intanto la campagna vaccinale anti-Covid, che in questa prima fase riguarda il personale della sanità e delle Cra, compresi i degenti delle residenze per anziani, gli ultraottantenni in assistenza domiciliare e i loro coniugi, se di 80 o più anni, e le persone dagli 85 anni in su; proseguono le prenotazioni per quelle dagli 80 agli 84 anni, iniziate il 1^ marzo. Alle ore 15 sono state somministrate complessivamente 432.404 dosi; sul totale, 146.244 sono seconde dosi, e cioè le persone che hanno completato il ciclo vaccinale. Prosegue l’attività di controllo e prevenzione: dei nuovi contagiati, 1.101 sono asintomatici individuati nell’ambito delle attività di contact tracing e screening regionali. Complessivamente, tra i nuovi positivi 621 erano già in isolamento al momento dell’esecuzione del tampone, 839 sono stati individuati all’interno di focolai già noti. L’età media dei nuovi positivi di oggi è 41,7 anni. Sui 1.101 asintomatici, 614 sono stati individuati grazie all’attività di contact tracing, 53 attraverso i test per le categorie a rischio introdotti dalla Regione, 67 con gli screening sierologici, 13 tramite i test pre-ricovero. Per 354 casi è ancora in corso l’indagine epidemiologica. La situazione dei contagi nelle province vede Bologna con 562 nuovi casi e Modena con 442; poi Ravenna (249), Reggio Emilia (246), Rimini (219), Cesena (208), Parma (169) e Ferrara (152). Seguono il territorio di Forlì (126), il circondario di Imola (111) e la provincia di Piacenza (61). Questi i dati - accertati alle ore 12 di oggi sulla base delle richieste istituzionali - relativi all’andamento dell’epidemia in regione. Nelle ultime 24 ore sono stati effettuati 20.833 tamponi molecolari, per un totale di 3.477.649. A questi si aggiungono anche 894 test sierologici e 17.398 tamponi rapidi. Per quanto riguarda le persone complessivamente guarite, sono 1.070 in più rispetto a ieri e raggiungono quota 211.352. I casi attivi, cioè i malati effettivi, a oggi sono 48.128 (+1.450 rispetto a ieri). Di questi, le persone in isolamento a casa, ovvero quelle con sintomi lievi che non richiedono cure ospedaliere o risultano prive di sintomi, sono complessivamente 45.269 (+1.367), il 94% del totale dei casi attivi. I pazienti ricoverati in terapia intensiva sono 259 (+8 rispetto a ieri), 2.600 quelli negli altri reparti Covid (+75). Sul territorio, i pazienti ricoverati in terapia intensiva sono così distribuiti: 9 a Piacenza (-1 rispetto a ieri), 15 a Parma (+1), 22 a Reggio Emilia (+2), 51 a Modena (-2), 72 a Bologna (+4), 24 a Imola (+1). Ancora, 25 a Ferrara (+1), 8 a Ravenna (+1), 6 a Forlì(+1), 7 a Cesena (invariato) e 20 a Rimini (invariato). Questi i casi di positività sul territorio dall’inizio dell’epidemia, che si riferiscono non alla provincia di residenza, ma a quella in cui è stata fatta la diagnosi: 20.239 a Piacenza (+61 rispetto a ieri, di cui 47 sintomatici), 18.413 a Parma (+169, di cui 76 sintomatici), 34.210 a Reggio Emilia (+246, di cui 142 sintomatici), 47.001 a Modena (+442, di cui 248 sintomatici), 55.927 a Bologna (+562, di cui 311 sintomatici), 9.608 casi a Imola (+111, di cui 61 sintomatici). Poi 15.563 a Ferrara (+152, di cui 46 sintomatici), 20.635 a Ravenna (+249, di cui 147 sintomatici), 10.289 a Forlì (+126, di cui 102 sintomatici), 12.674 a Cesena (+208, di cui 134 sintomatici) e 25.596 a Rimini (+219, di cui 130 sintomatici). Rispetto a quanto comunicato nei giorni scorsi, sono stati eliminati 20 casi, positivi a test antigenico ma non confermati da tampone molecolare.
Keep food fresher for longer with one of these energy efficient models
(henceforth, referred to as the forecast period). ? - The global pharmaceutical industry is growing at an exponential rate and is expected to reach USD 1. 52 trillion in annual sales by 2023, which is driven by global economic growth, a growing and aging population, and new product launches.New York, March 04, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Biologics Contract Development and Manufacturing Organization (CDMO) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" - https://www.reportlinker.com/p06030507/?utm_source=GNW Even though small molecules continue to command the prominent share of the market, large molecules, such as biologics, biosimilars, and cell and gene therapies, are expected to witness the fastest growth over the forecast period. ?- Even though volumes in large molecules tend to be smaller, the segment is growing at a faster pace. Absolute growth in the large molecules market, including both originator biologics, biosimilars, and cell and gene therapies, is projected at USD 133 billion by 2023. The market size for originator biologics is expected to reach USD 371 billion by 2023, according to Results Healthcare. ?- Cancer therapies are among the primary drivers for a large proportion of the growth in the biologics market. Even with the faster growth forecast, in terms of drug approvals, small molecules outweigh biologics. For instance, in 2018, the FDA approved 42 new small molecule products, whereas biologics approval amounted to just 17. However, the number of biologic approvals has been increasing steadily over the past few years.?- The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19 pandemic. This pandemic has impacted multiple aspects of the biopharma industry, from drug development, clinical trials, supplies, manufacturing, to supply chain logistics. However, the drug shortages due to COVID-19 are limited, and they are expected to remain so for short-term, due to stockpiles of pharmaceuticals, APIs, globally. Among the issues being faced across the supply chains, China and India have been impacted the most due to being the largest global producers of active pharmaceutical ingredients (APIs) and generics.?- Since lockdowns were imposed, supply from Chinese manufacturing facilities were significantly reduced. The major extent has been a number of typical workforce who were unable to return to work, which led to underutilized efficiency across multiple levels in the industry. Furthermore, short-term scarcities were announced by the US Food and Drug Administration (FDA) back in February 2020, due to API manufacturing delays. ?Key Market TrendsBiologics to Drive the Market- Monoclonal antibodies or synthetic versions of the antibody have been representative of most successful therapeutic drug classes and attract huge investment for the biologics industry. The use of monoclonal antibodies to treat diseases is called immunotherapy therapy because each type of monoclonal antibody will target a specifically targeted antigen in the body.?- Mammalian cells are traditionally used for monoclonal antibody production, however, plant-based expression systems have been gaining share sue to significant advantages. The advancements in plant glycoengineering have allowed the production of monoclonal antibodies (mAbs) with more homogenous human-like glycans. ?iBio’s proprietary plant-based technology instead of CHO or other mammalian cell technologies led the development of monoclonal antibody vectors free of any viral transforming functions or contamination from parental lines.?- Recombinant biologics are being developed by a process wherein a genetic code for a specific therapeutic protein is inserted into an expression vector’s DNA. The inserted DNA codes leads to recombinant protein being produced through replication in living host cells. Since the first recombinant therapeutic antibody (OKT3) in 1986, biologics products became a larger pharmaceutical industry percentage. ?- Since biologics have been dominating the human drug development because of their long-lasting effects and ability to precisely address the molecular causes of disease, only one recombinant protein drug, an antibody, is available for veterinary use in the U.S. or EU.?- Likewise, in February 2020, Invetx, invested USD 15 million Series A financing and undertook collaborations with WuXi Biologics and AbCellera. This is expected to drive clinical entry of a first therapeutic candidate and preclinical development of Invetx’s broader pipeline of protein-based therapeutics for Animal Biopharmaceutical Development.?North America to Dominate the Market- North America is one of the major markets for the biologics CDMO industry, owing to the presence of two major economies, such as the United States and Canada. The United States is home to one of the major pharmaceutical industries in the world and commands a significant share of the industry revenue; according to IQVIA, in 2019, the United States held about 48% of the global pharmaceutical market sales and seeing a steady growth in the last couple of years.?- The United States is the world’s largest market for drugs and accounts for almost half of the R&D spending in pharmaceutical and biotechnology markets. Hence, biologic CDMOs play a critical role in this market and have invested in new facilities and technologies to cater to a wide range of outsourcers.?- Moreover, the R&D expenditure of the total US pharmaceutical industry in 2018 was around USD 79.6 billion, according to PhRMA. With such a prominent presence in the market, the biologics CDMO vendors in the region are expected to scale up their presence and expand their capacities as well. For instance, AGC Biologics is looking to invest about USD 100 million into the AstraZeneca plant in Boulder; such developments are expected to increase over the coming years.?- Moreover, in August 2020, AGC Biologics, a global biopharmaceutical CDMO, partnered with Ono Pharmaceutical Co Ltd to manufacture its new biopharmaceutical at the clinical development stage. Such developments are expected to further increase over the coming years, further expanding the reach of CDMOs in biologics.?- In addition to this, global biologics CDMO vendors are increasing their investments and are expanding their presence in the region. For example, in March 2020, Bora Pharmaceuticals expanded its footprint in North America. Over the coming years, CDMOs are expected to expand their presence in the region due to the growing health ailments and aging population.?Competitive LandscapeThe Biologics Contract Development and Manufacturing Organization (CDMO) Market is highly fragmented and consists of several major players. They have adopted different strategies such as expansions, agreements, new product launches, joint ventures, acquisitions, partnerships, and others to expand their footprints in this market. Major players of the market include Boehringer Ingelheim Group, Wuxi Biologics, Samsung Biologics, Lonza Group, and Fujifilm Diosynth Biotechnologies USA Inc among others.- Aug 2020 - The Lonza Group AG announced to collaborate with IsoPlexis to Enable the Next Generation of Precision Cell Therapy Manufacturing. The company plan utilize IsoPlexis IsoLight automated proteomics platform, to scale the manufacturing of cell therapies- July 2020 - Boehringer Ingelheim, has acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company. GST is dedicated to the research, development, and production of evidence-based, regenerative medicines (stem cell therapies) used to treat orthopedic and metabolic diseases in animals.- May 2020 - WuXi Biologics and the Worcester Business Development Corporation (WBDC) announced the successful signing of a land deal for WuXi Biologics’ clinical and commercial manufacturing facility (MFG11) in Worcester at The Reactory, a 46-acre master-planned biomanufacturing campus.Reasons to Purchase this report:- The market estimate (ME) sheet in Excel format- 3 months of analyst supportRead the full report: https://www.reportlinker.com/p06030507/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Dr Igi Moon is a chartered psychologist whose work focuses on psychotherapy, gender, sexuality and emotion. They are also chair of the Coalition for the Memorandum of Understanding (MoU) Against Conversion Therapy, which includes 17 major therapy organisations, such as BPS and UKCP, GPs, NHS England and NHS Scotland, and is pushing for a ban on conversion therapy in the UK.
AARP The Magazine on Thursday unveiled its winners for the annual Movies for Grownups Awards, handing Hulu’s The United States vs. Billie Holiday its top prize, Best Picture/Best Movie for Grownups. Sophia Loren for Netflix’s The Life Ahead and Anthony Hopkins for Sony Classics’ The Father were named Best Actor and Best Actress, respectively, while […]
Public Health England has designated it a "variant under investigation" after 16 cases were confirmed.
Live updates from the White House
Photo Illustration by The Daily Beast / Photos Handout/GettyTrader Joe’s is reinstating an employee who was fired after criticizing the company’s COVID safety policies to the CEO, The Daily Beast has confirmed.On Wednesday evening, the popular grocery chain offered to reinstate Ben Bonnema, an employee at one of the grocery chain’s New York stores who wrote a letter to CEO Dan Bane admonishing the company for not taking adequate safety measures to keep workers safe from COVID-19. His initial firing went viral on social media and received national news attention.“It’s been a stressful week since then, but it makes sense that they offered to reinstate because it was a completely unlawful termination,” Bonnema said in a brief telephone call with The Daily Beast on Thursday.Late last month, the grocery store employee posted to Twitter that he was fired for sending the letter demanding better air-filtration systems in Trader Joe’s stores, a limit on the number of customers in stores, and a requirement for customers to wear masks. Bonnema also posted a note from the grocery chain that directly attributed his termination at an Upper West Side store to his letter.trader joe's just fired me for sending this letter to the ceo, saying i don't share the company values. i guess advocating for a safer workplace isn't a company value? pic.twitter.com/3TKi5B8HSJ— Ben Bonnema (@BenBonnema) February 26, 2021 The tweets quickly gained traction online. A scientist who Bonnema cited in his letter tweeted his support for the ousted Trader Joe’s staffer, and the former head of the Department of Occupational Safety and Health Administration shared Bonnema’s story, saying it was a “violation of the Occupational Safety and Health Act to retaliate against a worker for raising safety concerns.”here's the letter they gave me pic.twitter.com/BeYmopbmJ3— Ben Bonnema (@BenBonnema) February 26, 2021 Bonnema told The Daily Beast he and another crew member had several discussions with management at their store to discuss air-filtration measures, but decided to write an email to the CEO after they felt their concerns were not being addressed.Three days after writing the letter, Bonnema said, he was pulled aside during a shift and told he was being fired for the suggestions he made in his note, which managers said did not align with the company’s “core values.”In an initial statement after Bonnema was fired, a company spokesperson denied the decision was related to his letter to the CEO, instead attributing the termination to “disrespect he showed toward our customers.”But on Thursday, Bonnema’s lawyer Ben Dictor said the company’s quick reinstatement showed the spokesperson’s statement—which appeared in many national outlets including CNN and The Washington Post—was ultimately false. (Dictor is a labor attorney who also represents the NewsGuild, a media workers’ union that represents staffers at many outlets, including The Daily Beast’s editorial union).“While we are pleased that Mr. Bonnema has been rightfully reinstated, we will continue to take all necessary legal action to repair his reputation that has been disparaged by the company through false accusations that my client engaged in misconduct,” Dictor said. “We are also committed to ensuring that no essential workers of Trader Joe’s face any further retaliation for raising concerns about their working conditions.”Bonnema said he is still waiting to hear if OSHA will be hearing his concerns about improving air-filtration systems in Trader Joe’s stores while the coronavirus continues to threaten unvaccinated grocery workers and employees. But he’s not wasting any time returning to work: Bonnema said he plans to be back on Monday.Read more at The Daily Beast.Get our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.
A poll of 800 Torontonians conducted at the end of February found strong disapproval for contracted-out patient care at University Health Network’s (UHN) Hillcrest Reactivation Centre, where care staff are paid poorly and believe that the hospital is using them as "exploited" labour.
With the right preparation, specialist destinations can benefit from an expected increase in demand.